ICR in a medical context most commonly stands for insulin-to-carbohydrate ratio, a number used by people with diabetes to calculate how much insulin they need before a meal. The abbreviation also appears in oncology, pathology, and hospital quality reporting, so the meaning depends on the clinical setting. Here’s what each one refers to and why it matters.
Insulin-to-Carbohydrate Ratio
This is the most widely used medical meaning of ICR. Your insulin-to-carbohydrate ratio tells you how many grams of carbohydrate one unit of rapid-acting insulin will cover. If your ICR is 1:10, that means one unit of insulin handles about 10 grams of carbs. It’s a core tool for anyone on an intensive insulin regimen, particularly people with type 1 diabetes, because it turns carb counting into an actual dosing calculation rather than a guess.
A common method for estimating your ICR is the “500 rule.” You divide 500 by your total daily dose of insulin (basal plus mealtime combined). So if you take 50 units total per day, 500 รท 50 = 10, giving you an ICR of 1:10. Younger children or people whose total daily dose is relatively low for their body weight often use a “300 rule” instead, which produces a more conservative ratio. Either way, the result is a starting point that your care team fine-tunes over time.
Your ICR isn’t a single fixed number. It can differ at breakfast compared to lunch, shift during puberty or menstruation, and change with your activity level or if you’re sick. The American Diabetes Association recommends reviewing insulin dosing plans every three to six months to keep ratios aligned with how your body is actually responding. Most adults with type 1 diabetes start with a total daily dose somewhere between 0.4 and 1 unit per kilogram of body weight, with roughly half going toward mealtime boluses and half toward background (basal) insulin.
The Institute of Cancer Research
In oncology, ICR often refers to the Institute of Cancer Research, a London-based research institution with over a century of work in cancer science. The ICR was the first to provide evidence that DNA damage causes cancer, and the first institution in Europe to develop chemotherapy drugs. Several of those early drugs, including carboplatin and chlorambucil, are still used worldwide more than 50 years later.
More recently, the ICR discovered and developed abiraterone, a life-extending treatment for advanced prostate cancer. Since 2005, the institute has discovered 21 cancer drug candidates and moved 12 into clinical trials. It also pioneered an approach called synthetic lethality for treating cancers in people who carry BRCA1 or BRCA2 gene mutations. A drug combination developed through the ICR’s collaboration with The Royal Marsden hospital was recently approved in the United States for a rare form of ovarian cancer.
Intracavitary Radiation
ICR sometimes appears in radiation oncology shorthand for intracavitary radiation, a form of brachytherapy in which a sealed radiation source is placed inside a body cavity to deliver treatment directly to a tumor. It’s most commonly used for cervical cancer, though brachytherapy in general also treats cancers of the head and neck, breast, prostate, and eye.
There are two main approaches. Low-dose-rate (LDR) treatments leave the radiation source in place for one to seven days, typically requiring a hospital stay. High-dose-rate (HDR) treatments deliver radiation in sessions lasting just 10 to 20 minutes, repeated over several days or weeks on an outpatient basis. Your treatment schedule depends on the type and stage of cancer.
Invasive Cribriform Carcinoma
In pathology reports, ICR (or ICC) can refer to invasive cribriform carcinoma, a relatively rare subtype of breast cancer. Under a microscope, the tumor forms irregular island-shaped clusters with a mesh-like internal structure. The clinical significance here is the prognosis: studies show a 10-year survival rate of 90% to 100% for classical invasive cribriform carcinoma, which is notably better than the more common invasive ductal carcinoma.
Intensive Care Registries
In hospital administration and quality improvement, ICR can stand for an in-hospital clinical registry, particularly one focused on intensive care. These registries systematically collect data on ICU outcomes like mortality rates, infection rates, duration of mechanical ventilation, unplanned readmissions, and hospital length of stay. The goal is benchmarking: comparing a unit’s performance against its own history and against other units regionally or nationally, so hospitals can identify where care quality is slipping or improving. Some registries also track patient-reported outcomes, capturing how survivors perceive their recovery and health status after discharge.